Air descemetopexy is a safe and effective option for the management of Descemet detachment after cataract surgery
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
New microbial strain produces high yields of lutein for AMD, cataract prevention
Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis
Higher Molar Dose and Its Translation into Clinical Practice
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
Clareon Panoptix Pro IOL (Alcon) approved in Canada
The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation
Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia